3MH-2: Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

Sponsor

The University of Texas Medical Branch, Galveston (Other)

Overall Status

Completed

CT.gov ID

NCT01694602

Collaborator

(none)

Enrollment

Location

30.9

Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The overall aim of this research is to develop a non-invasive approach to evaluate the production of 3-methylhistidine (3MH)in cancer patients, as a potential means of determining which patients are at high risk for future development of cancer induced skeletal muscle atrophy.

Rationale: The approach is based on the hypothesis that after an oral dose of deuterated 3-methylhistidine (D-3MH), the slope of the terminal portion of the decay curve (> 12 hours post-dosing) for the tracer/tracee (D-3MH/3MH) in the free 3MH pool is proportional to the rate constant for myofibrillar protein degradation and can be determined from spot urine samples.

Condition or Disease	Intervention/Treatment	Phase
Cachexia	Biological: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)

Detailed Description

The long-term objective of this research is to develop a non-invasive approach for assessment of de novo 3MH production in cancer patients early in the course of the disease as a way of assessing which patients are at high risk for future development of skeletal muscle atrophy. The approach is based on: 1) the known increase in de novo production of 3-methylhistidine (3MH) from muscle protein breakdown in said patients as a consequence of their unique disease-host interactions, and 2) earlier demonstration that de novo 3MH production can be measured in vivo using isotope dilution.

During this Phase-II project, we propose to conduct a statistically powerful prospective investigation to demonstrate that measurement of the slope of the terminal decay curve (rate constant) with our approach in newly diagnosed cancer patients predicts future development of muscle wasting. We expect the outcome of the combined Phase-I and Phase-II research to lead to the early identification of elevated muscle catabolism in at-risk patients so that medical intervention can prevent future muscle atrophy.

Study Design

Study Type:

Observational

Actual Enrollment :

8 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase 2

Study Start Date :

Nov 1, 2012

Actual Primary Completion Date :

Jun 1, 2015

Actual Study Completion Date :

Jun 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Newly Diagnosed NSCLC patients In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).	Biological: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH) Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.

Arm

Intervention/Treatment

Newly Diagnosed NSCLC patients

In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).

Biological: (non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)

Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.

Outcome Measures

Primary Outcome Measures

Determination of myofibrillar protein degradation rate constant and slope of terminal decay curve. [Spot urine (multiple) collections between 12 to 17 hours of D-3MH ingestion.]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

(1) histological or cytological evidence of NSCLC without curative options;
(2) over 18 years of age;
(3) patient reported weight loss of ≤5% of usual body weight in the last 6 months;
(4) life expectancy of greater than 6 months based on the judgement of treating physician;
(5) serum creatinine ≤1.5 times the upper limit of normal; and
(6) willing and able to give informed consent.

Exclusion Criteria:

1. malabsorption, intractable vomiting or gastrointestinal obstruction
1. congestive heart failure
1. edema or ascites
1. liver function test results that will preclude administration of prescribed therapy
1. pregnant, nursing, or, if of child-bearing age, unwilling to use contraceptives